Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigator Initiated Prospective Study to Investigate the Best Anti-platelet Treatment in High Thrombotic Risk PCI Patients.

Next Previous
X
Search
Trial Profile

Investigator Initiated Prospective Study to Investigate the Best Anti-platelet Treatment in High Thrombotic Risk PCI Patients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilostazol (Primary) ; Aspirin; Clopidogrel
  • Indications Stent thrombosis
  • Focus Therapeutic Use
  • Acronyms CREATIVE

    • Most Recent Events

    • 02 Feb 2018 Results comparing safety and efficacy of Double-Dose Clopidogrel or Adjunctive Cilostazol versus Standard Dual Anti-platelet therapy, published in the Circulation.
    • 18 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 13 Aug 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Sep 2016 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top